Overview

Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study

Status:
Withdrawn
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine if apixaban is more safe, when compared to warfarin, at reducing the risk of bleeding during CIED procedures.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
Bristol-Myers Squibb
Treatments:
Apixaban
Warfarin